ADAURA has not and will not impact my use of adjuvant chemotherapy. Many prospective studies have demonstrated a clear significant improvement in overall survival with the use of adjuvant chemotherapy after complete surgical resection. This is standard of care for the appropriate patients. Osimertin...

I will continue to use chemotherapy in the adjuvant setting in stage 2 and 3 disease, as that has shown a clear survival benefit.

I believe the decision regarding adjuvant chemotherapy should be made independently of the decision to use osimertinib. As before, I strongly advise adjuvant cisplatin-based chemotherapy for lymph node-positive tumors, and consider it for larger lymph node-negative tumors, for patients with adequate...

Adjuvant chemotherapy has proven to increase cure rates.  Adjuvant Osimertinib has only proven to increase disease-free survival.  This improvement in disease-free survival may still result in an overall survival benefit.  The data is not mature enough to make this determination. ...